The Center for Hypertension of the People's Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang China, Xinjiang, China .
J Interferon Cytokine Res. 2018 Sep;38(9):406-412. doi: 10.1089/jir.2017.0140.
Monocyte chemotactic protein 1 (MCP-1) plays a significant role in inflammation pathways by affecting monocyte/macrophage migration, the number of monocytes and T lymphocytes, and osmosis. Inflammation is closely linked to various types of systematic vasculitis. Here we characterized serum MCP-1 levels in systemic vasculitis patients. This cross-sectional study included serum samples collected from 43 patients with systemic vasculitis and 43 healthy controls (HCs). Serum MCP-1 levels in the samples were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Serum MCP-1 levels were significantly higher in patients with systemic vasculitis relative to HCs (parentheses indicate quartile values) [134.65 (73.74, 262.75) pg/mL versus 59.1 (37.41, 90.18) pg/mL, P < 0.001]. Furthermore, systemic vasculitis patients having renal involvement had significantly higher MCP-1 levels relative to patients without renal involvement [196.16 (104.41, 310.35) pg/mL versus 73.74 (41.24, 145.95) pg/mL, P = 0.001] and HCs [196.16 (104.41, 310.35) pg/mL versus 59.10 (37.41, 90.18) pg/mL, P < 0.001]. Serum MCP-1 levels in systemic vasculitis patients were positively correlated with serum creatinine levels (r = 0.387, P < 0.010) and with 24-h proteinuria (r = 0.404, P < 0.014). Receiver operating characteristic (ROC) analysis showed that the cutoff value for MCP-1 to distinguish systemic vasculitis from HCs was 72.73 pg/mg, and the area under the ROC curve was 0.772. The sensitivity and specificity were 76.7% and 72.1%, respectively. Serum MCP-1 levels were significantly higher in patients with systemic vasculitis than in HCs, especially in patients with renal involvement. Thus, serum MCP-1 has the potential to be a biomarker for systemic vasculitis with renal involvement.
单核细胞趋化蛋白 1（MCP-1）通过影响单核细胞/巨噬细胞迁移、单核细胞和 T 淋巴细胞数量以及渗透作用，在炎症途径中发挥重要作用。炎症与各种类型的系统性血管炎密切相关。在这里，我们对系统性血管炎患者的血清 MCP-1 水平进行了特征描述。本横断面研究纳入了 43 例系统性血管炎患者和 43 例健康对照者（HCs）的血清样本。使用商业上可获得的酶联免疫吸附测定（ELISA）试剂盒测量样本中的血清 MCP-1 水平。与 HCs 相比，系统性血管炎患者的血清 MCP-1 水平显著升高（括号中表示四分位数）[134.65（73.74，262.75）pg/mL 与 59.1（37.41，90.18）pg/mL，P<0.001]。此外，与无肾脏受累的患者相比，有肾脏受累的系统性血管炎患者的 MCP-1 水平显著更高[196.16（104.41，310.35）pg/mL 与 73.74（41.24，145.95）pg/mL，P=0.001]和 HCs [196.16（104.41，310.35）pg/mL 与 59.10（37.41，90.18）pg/mL，P<0.001]。系统性血管炎患者的血清 MCP-1 水平与血清肌酐水平呈正相关（r=0.387，P<0.010），与 24 小时蛋白尿呈正相关（r=0.404，P<0.014）。受试者工作特征（ROC）分析显示，MCP-1 区分系统性血管炎与 HCs 的截断值为 72.73pg/mg，ROC 曲线下面积为 0.772。灵敏度和特异性分别为 76.7%和 72.1%。与 HCs 相比，系统性血管炎患者的血清 MCP-1 水平显著升高，尤其是有肾脏受累的患者。因此，血清 MCP-1 有可能成为伴有肾脏受累的系统性血管炎的生物标志物。
